Skip to content

HSJS-092404 shots study for exercise performance improvement in Gym goers

An Open label, Prospective, Single arm, Clinical Study to Evaluate the Safety and Efficacy of HSJS-092404 in Improving Exercise Performance in Healthy Adult Subjects. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085632
Enrollment
50
Registered
2025-04-25
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Himalaya Wellness Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. 18-40 years predominantly males and fitness enthusiastic females. 2. Athletes, sports or fitness enthusiasts engaged in regular resistance training (comprising of cardio and strength training like pushups, bench press, leg press, squats etc) from last 6 months for at least 5 days in a week and willing to continue throughout the study duration. 3. Subjects who agree to perform physical activities as stated in the protocol. 4. Subjects who agree not to start any new therapies or energy boosting supplements or protein supplements or health drinks during the study. 5. Subjects who have not participated in any other similar clinical study in the last 3 months. 6. Subjects willing to sign informed consent and follow the study procedure. 7.Women of child-bearing potential must agree to use adequate contraception during study period 8.Male participants who are willing to refrain from donating sperm from first admission to the study until 90 days after the study completion

Exclusion criteria

Exclusion criteria: 1.Subjects who have any physical disability which could interfere with their ability to perform the functional performance measures included in this protocol. 2.Subjects with known clinically significant neurological, respiratory, cardiovascular, gastrointestinal, hepatic, congenital or any other chronic disorder that can interfere with the study conduct in the opinion of the Investigator. 3.Subjects with known history or present condition of allergic response to any of the ingredients in the investigational product. 4.Pre-existing systemic diseases (auto immune disorders, hormonal replacement, etc.) necessitating long-term medications or any other such as bleeding disorders. 5.Pregnant as assessed by UPT & History of Amenorrhea and lactating women. 6.Known history of drug abuse/dependency that would limit ability to comprehend or follow instructions related to informed consent, treatment instructions, study procedures or follow-up guidelines. 7.Any other conditions (physical, psychological, social or uncontrolled dietary measures) that can interfere with the participant s compliance to the study in the opinion of the Investigator

Design outcomes

Primary

MeasureTime frame
Improvement in workout performance and muscle endurance using Push-up test. Improvement in muscle strength & muscle recovery using Hand Grip Strength test. Improvement in Energy Stamina Muscle Endurance Strength Muscle Recovery and Workout Performance through Subject Perception questionnaire.Timepoint: Visit 1: Screening/Day 1 Visit 2: Day 30 2 days Visit 3: Day 60 2 days Visit 4: Day 90 2 days

Secondary

MeasureTime frame
Assessment of safety of Investigational Product through General Physical Examination & Laboratory Investigations. Incidence of adverse events during the study period. Assessment of GI (Gastrointestinal) tolerability through GSRS (Gastrointestinal Symptom Rating Scale). Proportion of subjects withdrawing from trial because of adverse events (tolerability).Timepoint: Visit 1: Screening/Day 1 Visit 2: Day 30 2 days Visit 3: Day 60 2 days Visit 4: Day 90 2 days

Countries

India

Contacts

Public ContactDr Soorya Narayan H

Himalaya Wellness Company

rajesh.kumawat@himalayawellness.com8067549904

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026